Business Context and Reporting Period
This Form 8-K Current Report was filed by Corbus Pharmaceuticals Holdings, Inc. on April 15, 2026. The filing discloses the execution of amended and restated employment agreements with two key executive officers: Yuval Cohen, Ph.D., Chief Executive Officer, and Sean Moran, Chief Financial Officer. The agreements are effective as of April 15, 2026, and extend through April 15, 2028.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
- CEO Base Salary: $673,625 annually.
- CFO Base Salary: $501,273 annually.
- CEO Target Bonus: Up to 60% of base salary.
- CFO Target Bonus: Up to 40% of base salary.
Material Changes Versus Prior Period
The filing details the renewal and amendment of employment contracts for the CEO and CFO. These agreements replace prior arrangements with new terms effective April 15, 2026, establishing a two-year term for both executives. No comparative financial data or prior period contract terms are provided in this text to quantify changes in compensation structure relative to previous agreements.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The filing contains no forward-looking financial guidance, operational outlook, or strategic commentary beyond the confirmation of executive retention.
Risks and Contingencies:
- Severance Obligations: Significant contingent liabilities exist if employment is terminated without cause or for good reason.
- CEO: 12 months of base salary (24 months during a Change in Control Period) plus COBRA coverage and potential pro-rated or accelerated bonuses.
- CFO: 12 months of base salary (18 months during a Change in Control Period) plus COBRA coverage and potential pro-rated or accelerated bonuses.
- Equity Acceleration: In the event of a Change in Control followed by termination, both executives are eligible for accelerated vesting of all outstanding equity awards.
- Golden Parachute Provisions: Severance payments are subject to reduction under Internal Revenue Code Section 4999 to avoid excise taxes.
- Non-Compete Covenants: Executives are subject to non-compete provisions for 6 months post-employment (conditional on severance receipt) and non-solicitation provisions for 12 months.
Key Facts for Investor Verification
- Verify the total potential cash and equity payout obligations for the CEO and CFO under various termination scenarios (without cause, good reason, and Change in Control).
- Confirm the current outstanding equity awards held by Dr. Cohen and Mr. Moran to assess the impact of potential acceleration clauses.
- Review the company's cash position to ensure liquidity is sufficient to cover potential severance liabilities if a Change in Control occurs.
- Check for any subsequent filings regarding the adoption of new equity incentive plans referenced in the agreements.